カテゴリ： 世界, 医療/バイオ, QYResearch

原発性硬化性胆管炎（PSC）の世界市場2023年：医療、肝移植、その他

■ 英語タイトル：Global Primary Sclerosing Cholangitis (PSC) Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA3084）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA3084
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：102
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[原発性硬化性胆管炎（PSC）の世界市場2023年：医療、肝移植、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は原発性硬化性胆管炎（PSC）のグローバル市場について調査・分析し、世界の原発性硬化性胆管炎（PSC）市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（医療、肝移植、その他）、用途別セグメント分析（病院、クリニック、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Acorda Therapeutics、Gilead Sciences、NGM Biopharmaceuticals、Intercept Pharmaceuticals、Dr. Falk Pharma、Allergan、Shire、Durect Corporation、Conatus Pharmaceuticals、Sirnaomics、Shenzhen HighTide Biopharmaceutical、Glenmark、Impax Laboratories、Mylan、Teva Pharmaceuticals、Daewoong Pharmaceutical、Mitsubishi Tanabe Pharma、Lannettなどが含まれています。原発性硬化性胆管炎（PSC）のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、原発性硬化性胆管炎（PSC）市場規模を算出する際に考慮しました。

・原発性硬化性胆管炎（PSC）市場の概要
- 原発性硬化性胆管炎（PSC）の種類別セグメント
- 世界の原発性硬化性胆管炎（PSC）市場規模：タイプ別分析（医療、肝移植、その他）
- 原発性硬化性胆管炎（PSC）の用途別セグメント
- 世界の原発性硬化性胆管炎（PSC）市場規模：用途別分析（病院、クリニック、その他）
- 世界の原発性硬化性胆管炎（PSC）市場規模予測（2018年-2029年）

・原発性硬化性胆管炎（PSC）市場の成長トレンド
- 原発性硬化性胆管炎（PSC）の地域別市場規模（2018年-2029年）
- 原発性硬化性胆管炎（PSC）市場ダイナミクス
- 原発性硬化性胆管炎（PSC）の業界動向
- 原発性硬化性胆管炎（PSC）市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：医療、肝移植、その他
- 世界の原発性硬化性胆管炎（PSC）のタイプ別市場規模（2018年-2023年）
- 世界の原発性硬化性胆管炎（PSC）のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、クリニック、その他
- 世界の原発性硬化性胆管炎（PSC）の用途別市場規模（2018年-2023年）
- 世界の原発性硬化性胆管炎（PSC）の用途別市場規模（2024年-2029年）

・原発性硬化性胆管炎（PSC）の地域別市場規模
- 北米の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- 米国の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- ヨーロッパの原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- アジア太平洋の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- 中国の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- 日本の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- 韓国の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- インドの原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- オーストラリアの原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- 中南米の原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）
- 中東・アフリカの原発性硬化性胆管炎（PSC）市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Acorda Therapeutics、Gilead Sciences、NGM Biopharmaceuticals、Intercept Pharmaceuticals、Dr. Falk Pharma、Allergan、Shire、Durect Corporation、Conatus Pharmaceuticals、Sirnaomics、Shenzhen HighTide Biopharmaceutical、Glenmark、Impax Laboratories、Mylan、Teva Pharmaceuticals、Daewoong Pharmaceutical、Mitsubishi Tanabe Pharma、Lannett

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Primary Sclerosing Cholangitis (PSC) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Primary Sclerosing Cholangitis (PSC) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Primary Sclerosing Cholangitis (PSC) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Primary Sclerosing Cholangitis (PSC) in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Primary Sclerosing Cholangitis (PSC) include Acorda Therapeutics, Gilead Sciences, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr. Falk Pharma, Allergan, Shire, Durect Corporation and Conatus Pharmaceuticals, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Primary Sclerosing Cholangitis (PSC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Sclerosing Cholangitis (PSC).
The Primary Sclerosing Cholangitis (PSC) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Primary Sclerosing Cholangitis (PSC) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Sclerosing Cholangitis (PSC) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Acorda Therapeutics
Gilead Sciences
NGM Biopharmaceuticals
Intercept Pharmaceuticals
Dr. Falk Pharma
Allergan
Shire
Durect Corporation
Conatus Pharmaceuticals
Sirnaomics
Shenzhen HighTide Biopharmaceutical
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Daewoong Pharmaceutical
Mitsubishi Tanabe Pharma
Lannett
Segment by Type
Medical Treatement
Liver Transplantation
Others
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Primary Sclerosing Cholangitis (PSC) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Medical Treatement
1.2.3 Liver Transplantation
1.2.4 Others
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis (PSC) Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis (PSC) Market Perspective (2018-2029)
2.2 Primary Sclerosing Cholangitis (PSC) Growth Trends by Region
2.2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Primary Sclerosing Cholangitis (PSC) Historic Market Size by Region (2018-2023)
2.2.3 Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Region (2024-2029)
2.3 Primary Sclerosing Cholangitis (PSC) Market Dynamics
2.3.1 Primary Sclerosing Cholangitis (PSC) Industry Trends
2.3.2 Primary Sclerosing Cholangitis (PSC) Market Drivers
2.3.3 Primary Sclerosing Cholangitis (PSC) Market Challenges
2.3.4 Primary Sclerosing Cholangitis (PSC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Sclerosing Cholangitis (PSC) Players by Revenue
3.1.1 Global Top Primary Sclerosing Cholangitis (PSC) Players by Revenue (2018-2023)
3.1.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Players (2018-2023)
3.2 Global Primary Sclerosing Cholangitis (PSC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Sclerosing Cholangitis (PSC) Revenue
3.4 Global Primary Sclerosing Cholangitis (PSC) Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis (PSC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis (PSC) Revenue in 2022
3.5 Primary Sclerosing Cholangitis (PSC) Key Players Head office and Area Served
3.6 Key Players Primary Sclerosing Cholangitis (PSC) Product Solution and Service
3.7 Date of Enter into Primary Sclerosing Cholangitis (PSC) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis (PSC) Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis (PSC) Historic Market Size by Type (2018-2023)
4.2 Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Type (2024-2029)
5 Primary Sclerosing Cholangitis (PSC) Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis (PSC) Historic Market Size by Application (2018-2023)
5.2 Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
6.2 North America Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
6.4 North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
7.2 Europe Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
7.4 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
8.2 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2018-2023)
8.4 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
9.2 Latin America Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
9.4 Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
10.2 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
10.4 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Acorda Therapeutics
11.1.1 Acorda Therapeutics Company Detail
11.1.2 Acorda Therapeutics Business Overview
11.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Introduction
11.1.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.1.5 Acorda Therapeutics Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Introduction
11.2.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 NGM Biopharmaceuticals
11.3.1 NGM Biopharmaceuticals Company Detail
11.3.2 NGM Biopharmaceuticals Business Overview
11.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.3.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.3.5 NGM Biopharmaceuticals Recent Development
11.4 Intercept Pharmaceuticals
11.4.1 Intercept Pharmaceuticals Company Detail
11.4.2 Intercept Pharmaceuticals Business Overview
11.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.4.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.4.5 Intercept Pharmaceuticals Recent Development
11.5 Dr. Falk Pharma
11.5.1 Dr. Falk Pharma Company Detail
11.5.2 Dr. Falk Pharma Business Overview
11.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Introduction
11.5.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.5.5 Dr. Falk Pharma Recent Development
11.6 Allergan
11.6.1 Allergan Company Detail
11.6.2 Allergan Business Overview
11.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Introduction
11.6.4 Allergan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.6.5 Allergan Recent Development
11.7 Shire
11.7.1 Shire Company Detail
11.7.2 Shire Business Overview
11.7.3 Shire Primary Sclerosing Cholangitis (PSC) Introduction
11.7.4 Shire Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.7.5 Shire Recent Development
11.8 Durect Corporation
11.8.1 Durect Corporation Company Detail
11.8.2 Durect Corporation Business Overview
11.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Introduction
11.8.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.8.5 Durect Corporation Recent Development
11.9 Conatus Pharmaceuticals
11.9.1 Conatus Pharmaceuticals Company Detail
11.9.2 Conatus Pharmaceuticals Business Overview
11.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.9.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.9.5 Conatus Pharmaceuticals Recent Development
11.10 Sirnaomics
11.10.1 Sirnaomics Company Detail
11.10.2 Sirnaomics Business Overview
11.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Introduction
11.10.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.10.5 Sirnaomics Recent Development
11.11 Shenzhen HighTide Biopharmaceutical
11.11.1 Shenzhen HighTide Biopharmaceutical Company Detail
11.11.2 Shenzhen HighTide Biopharmaceutical Business Overview
11.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Introduction
11.11.4 Shenzhen HighTide Biopharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.11.5 Shenzhen HighTide Biopharmaceutical Recent Development
11.12 Glenmark
11.12.1 Glenmark Company Detail
11.12.2 Glenmark Business Overview
11.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Introduction
11.12.4 Glenmark Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.12.5 Glenmark Recent Development
11.13 Impax Laboratories
11.13.1 Impax Laboratories Company Detail
11.13.2 Impax Laboratories Business Overview
11.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Introduction
11.13.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.13.5 Impax Laboratories Recent Development
11.14 Mylan
11.14.1 Mylan Company Detail
11.14.2 Mylan Business Overview
11.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Introduction
11.14.4 Mylan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.14.5 Mylan Recent Development
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Company Detail
11.15.2 Teva Pharmaceuticals Business Overview
11.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.15.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.15.5 Teva Pharmaceuticals Recent Development
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical Company Detail
11.16.2 Daewoong Pharmaceutical Business Overview
11.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Introduction
11.16.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.16.5 Daewoong Pharmaceutical Recent Development
11.17 Mitsubishi Tanabe Pharma
11.17.1 Mitsubishi Tanabe Pharma Company Detail
11.17.2 Mitsubishi Tanabe Pharma Business Overview
11.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Introduction
11.17.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.17.5 Mitsubishi Tanabe Pharma Recent Development
11.18 Lannett
11.18.1 Lannett Company Detail
11.18.2 Lannett Business Overview
11.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Introduction
11.18.4 Lannett Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.18.5 Lannett Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Medical Treatement
Table 3. Key Players of Liver Transplantation
Table 4. Key Players of Others
Table 5. Global Primary Sclerosing Cholangitis (PSC) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Primary Sclerosing Cholangitis (PSC) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Primary Sclerosing Cholangitis (PSC) Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Primary Sclerosing Cholangitis (PSC) Market Share by Region (2018-2023)
Table 9. Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Primary Sclerosing Cholangitis (PSC) Market Share by Region (2024-2029)
Table 11. Primary Sclerosing Cholangitis (PSC) Market Trends
Table 12. Primary Sclerosing Cholangitis (PSC) Market Drivers
Table 13. Primary Sclerosing Cholangitis (PSC) Market Challenges
Table 14. Primary Sclerosing Cholangitis (PSC) Market Restraints
Table 15. Global Primary Sclerosing Cholangitis (PSC) Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Primary Sclerosing Cholangitis (PSC) Market Share by Players (2018-2023)
Table 17. Global Top Primary Sclerosing Cholangitis (PSC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis (PSC) as of 2022)
Table 18. Ranking of Global Top Primary Sclerosing Cholangitis (PSC) Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Primary Sclerosing Cholangitis (PSC) Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Primary Sclerosing Cholangitis (PSC) Product Solution and Service
Table 22. Date of Enter into Primary Sclerosing Cholangitis (PSC) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Primary Sclerosing Cholangitis (PSC) Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Type (2018-2023)
Table 26. Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Type (2024-2029)
Table 28. Global Primary Sclerosing Cholangitis (PSC) Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Application (2018-2023)
Table 30. Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Application (2024-2029)
Table 32. North America Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029) & (US$ Million)
Table 47. Acorda Therapeutics Company Detail
Table 48. Acorda Therapeutics Business Overview
Table 49. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product
Table 50. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 51. Acorda Therapeutics Recent Development
Table 52. Gilead Sciences Company Detail
Table 53. Gilead Sciences Business Overview
Table 54. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product
Table 55. Gilead Sciences Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 56. Gilead Sciences Recent Development
Table 57. NGM Biopharmaceuticals Company Detail
Table 58. NGM Biopharmaceuticals Business Overview
Table 59. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product
Table 60. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 61. NGM Biopharmaceuticals Recent Development
Table 62. Intercept Pharmaceuticals Company Detail
Table 63. Intercept Pharmaceuticals Business Overview
Table 64. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product
Table 65. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 66. Intercept Pharmaceuticals Recent Development
Table 67. Dr. Falk Pharma Company Detail
Table 68. Dr. Falk Pharma Business Overview
Table 69. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product
Table 70. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 71. Dr. Falk Pharma Recent Development
Table 72. Allergan Company Detail
Table 73. Allergan Business Overview
Table 74. Allergan Primary Sclerosing Cholangitis (PSC) Product
Table 75. Allergan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 76. Allergan Recent Development
Table 77. Shire Company Detail
Table 78. Shire Business Overview
Table 79. Shire Primary Sclerosing Cholangitis (PSC) Product
Table 80. Shire Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 81. Shire Recent Development
Table 82. Durect Corporation Company Detail
Table 83. Durect Corporation Business Overview
Table 84. Durect Corporation Primary Sclerosing Cholangitis (PSC) Product
Table 85. Durect Corporation Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 86. Durect Corporation Recent Development
Table 87. Conatus Pharmaceuticals Company Detail
Table 88. Conatus Pharmaceuticals Business Overview
Table 89. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product
Table 90. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 91. Conatus Pharmaceuticals Recent Development
Table 92. Sirnaomics Company Detail
Table 93. Sirnaomics Business Overview
Table 94. Sirnaomics Primary Sclerosing Cholangitis (PSC) Product
Table 95. Sirnaomics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 96. Sirnaomics Recent Development
Table 97. Shenzhen HighTide Biopharmaceutical Company Detail
Table 98. Shenzhen HighTide Biopharmaceutical Business Overview
Table 99. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product
Table 100. Shenzhen HighTide Biopharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 101. Shenzhen HighTide Biopharmaceutical Recent Development
Table 102. Glenmark Company Detail
Table 103. Glenmark Business Overview
Table 104. Glenmark Primary Sclerosing Cholangitis (PSC) Product
Table 105. Glenmark Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 106. Glenmark Recent Development
Table 107. Impax Laboratories Company Detail
Table 108. Impax Laboratories Business Overview
Table 109. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product
Table 110. Impax Laboratories Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 111. Impax Laboratories Recent Development
Table 112. Mylan Company Detail
Table 113. Mylan Business Overview
Table 114. Mylan Primary Sclerosing Cholangitis (PSC) Product
Table 115. Mylan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 116. Mylan Recent Development
Table 117. Teva Pharmaceuticals Company Detail
Table 118. Teva Pharmaceuticals Business Overview
Table 119. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product
Table 120. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 121. Teva Pharmaceuticals Recent Development
Table 122. Daewoong Pharmaceutical Company Detail
Table 123. Daewoong Pharmaceutical Business Overview
Table 124. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product
Table 125. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 126. Daewoong Pharmaceutical Recent Development
Table 127. Mitsubishi Tanabe Pharma Company Detail
Table 128. Mitsubishi Tanabe Pharma Business Overview
Table 129. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product
Table 130. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 131. Mitsubishi Tanabe Pharma Recent Development
Table 132. Lannett Company Detail
Table 133. Lannett Business Overview
Table 134. Lannett Primary Sclerosing Cholangitis (PSC) Product
Table 135. Lannett Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023) & (US$ Million)
Table 136. Lannett Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Sclerosing Cholangitis (PSC) Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Primary Sclerosing Cholangitis (PSC) Market Share by Type: 2022 VS 2029
Figure 3. Medical Treatement Features
Figure 4. Liver Transplantation Features
Figure 5. Others Features
Figure 6. Global Primary Sclerosing Cholangitis (PSC) Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application: 2022 VS 2029
Figure 8. Hospital Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Primary Sclerosing Cholangitis (PSC) Report Years Considered
Figure 12. Global Primary Sclerosing Cholangitis (PSC) Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Primary Sclerosing Cholangitis (PSC) Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Primary Sclerosing Cholangitis (PSC) Market Share by Region: 2022 VS 2029
Figure 15. Global Primary Sclerosing Cholangitis (PSC) Market Share by Players in 2022
Figure 16. Global Top Primary Sclerosing Cholangitis (PSC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis (PSC) as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Primary Sclerosing Cholangitis (PSC) Revenue in 2022
Figure 18. North America Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Primary Sclerosing Cholangitis (PSC) Market Share by Country (2018-2029)
Figure 20. United States Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Primary Sclerosing Cholangitis (PSC) Market Share by Country (2018-2029)
Figure 24. Germany Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Share by Region (2018-2029)
Figure 32. China Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Primary Sclerosing Cholangitis (PSC) Market Share by Country (2018-2029)
Figure 40. Mexico Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Share by Country (2018-2029)
Figure 44. Turkey Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 47. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 48. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 49. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 50. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 51. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 52. Shire Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 53. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 54. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 55. Sirnaomics Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 56. Shenzhen HighTide Biopharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 57. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 58. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 59. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 60. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 61. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 62. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 63. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • フルサービス臨床研究機関（CRO）の世界市場2023年：臨床CRO、前臨床CRO
  • ストレージエリアネットワーク（SAN）の世界市場2023年：従来SAN、仮想SAN
  • デジタルビデオサーバー（DVS）の世界市場2023年：M-JPEG技術、MPEG-4技術、H.264技術
  • EaaSサービス（エネルギーアズアサービス）の世界市場2023年：エネルギー供給、運用＆保守、エネルギー効率化＆最適化
  • 非接触給電システム（CPT）の世界市場2023年：音響連動、光学連動、電界連動
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA3084 )"原発性硬化性胆管炎（PSC）の世界市場2023年：医療、肝移植、その他" (英文：Global Primary Sclerosing Cholangitis (PSC) Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。